Abstract
This new strategic report from Espicom provides a comprehensive review of
current and future treatments for major gastrointestinal therapy areas:
inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and
gastro-oesophageal reflux disease (GORD).
- Unique market share and 5-year sales forecasts for leading products &
prospects
- A comprehensive examination of major gastrointestinal therapy areas
- Critical competitive evaluation and scoring of current and up and coming
products
THE REPORT COVERS MAJOR DISEASE AREAS
Inflammatory bowel disease (Crohn' s disease & ulcerative colitis) Irritable
bowel syndrome Gastro-oesophageal reflux disease (GORD)
THE FACTS
Risk factors, how the disease affects patients, diagnosis and stages of the
disease
PATIENT STATISTICS
Prevalence in the US, Europe and Japan Diagnosis rates
CURRENT TREATMENT OPTIONS
Interventions by type Unique five point competitive assessment and scoring of
current therapies and companies involved Sales forecasts for key products to
2012
R&D: DRUGS IN PHASE II/III
Focus on new classes of drugs and the companies involved Unique competitive
assessment and scoring of new therapies and companies involved 5-year sales
forecasts for key products from year of launch
Providing…
- Detailed analysis and 5-year forecasts for current leading products by
value
- A detailed review and assessment of up and coming products
- Unique product evaluation and scoring
- An examination of the current understanding of IBD, IBS and GORD
View Cart
